These findings contribute to the evolving landscape of immune dysregulation in autoimmune diseases, pointing to the potential therapeutic benefit of pharmacological PD-1 activation to rebalance the autoimmune response and reduce inflammation. This evidence concerns the gene PDCD1 and autoimmune disease.